Medical cannabis and the problem of CBD regulation in Poland: quality, COA, availability (2026)

The Polish CBD product market in 2026 is a regulatory paradox. On one hand, thousands of patients receive Rpw prescriptions for medical marijuana produced under GMP conditions, on the other hand, CBD supplements in drugstores and online stores are subject only to general dietary supplement regulations. The result? In Bonn-Miller's 2017 audit published in JAMA, as much as 69% of CBD products had labels inconsistent with the actual concentration (Bonn-Miller et al., JAMA, 2017). This article explains how to distinguish a valuable product from marketing fiction, how to read a COA, how much therapy costs at the pharmacy, and what GIS, GIF, and PIH really do in the Polish CBD market. how to find a good CBD store – supplier evaluation criteria

The short answer: why is CBD regulation a problem for Polish patients?

In Poland in 2026, CBD operates under three separate legal regimes: as a medicinal product (medical marijuana, prescription Rpw), dietary supplement or cosmetic (over-the-counter), and an ambiguous category of hemp flowers. The lack of uniform regulation, the Novel Food status suspended by EFSA since 2022, and the dispersed oversight of GIF/GIS/PIH result in drastic fluctuations in product quality on the market (EFSA Journal 7322, 2022).

From a patient’s perspective, this is a problem in three dimensions. First, the same chemical compound (CBD) has three different access pathways and three different levels of quality control. Second, the cost of medical marijuana therapy in pharmacies can be prohibitive for many (1500-4800 PLN per month). Third, CBD supplements from online stores often do not contain the declared amount of cannabinoid, and some contain contaminants.

The result is a situation where a patient with chronic pain either waits weeks for an appointment with an Rpw doctor and pays for medical cannabis, or buys a CBD supplement with unknown active compound content. Meanwhile, the qualitative difference between these products does not stem from the chemistry of CBD, but from the control and oversight regime.

The Polish CBD market in 2026 is divided into three regimes: GMP medicinal products on prescription Rpw, dietary supplements and cosmetics from stores, and hemp flowers with ambiguous status. The Novel Food status was suspended by EFSA in 2022 after identifying gaps in toxicological data (EFSA Journal 7322, 2022).

What are medical cannabis and when did they reach Polish pharmacies?

Medical cannabis is standardized flower or extract from Cannabis sativa L. with a known cannabinoid profile, produced under Good Manufacturing Practice (GMP), dispensed in pharmacies only with a prescription Rpw. In Poland, it became legal on November 1, 2017, after the amendment to the Act on Counteracting Drug Addiction (Journal of Laws 2017, item 1458). The first filled Rpw prescription occurred in January 2019 after importing raw material from Canada.

The difference between medical marijuana and a typical CBD supplement is fundamental. Pharmaceutical flower has a label with the exact concentration of THC and CBD, batch number, production date, expiration date, and laboratory analysis results. No pesticides, heavy metals, mycotoxins, or microbiological contaminants. This is the pharmaceutical standard.

Legal definition of medical marijuana in Poland

Art. 33a of the Act on Counteracting Drug Addiction allows the trade of raw materials from cannabis other than fiber for pharmaceutical purposes, as an active substance for pharmacy formulations. In Polish pharmacies, it is available under the name "Cannabis Flos" and imported products from brands Aurora, Tilray, Bedrocan, and Spectrum. From 2024, domestic Polish flower from crops authorized by GIF will also be available in pharmacies.

The Rpw prescription (Rp. list) is issued for narcotic substances of groups I-N and II-N. It takes the form of a pink electronic print with dosage, quantity, and clinical indication annotations. It is valid for 30 days from the date of issuance. It is filled by a pharmacy with a GIF permit for the trade of narcotic substances. In the first quarter of 2026, there were over 4,200 authorized pharmacies in Poland, which is about 40% of all facilities.

What are over-the-counter CBD products?

Over-the-counter CBD products are oils, flowers, cosmetics, and supplements containing extract from hemp (Cannabis sativa L.) with THC content below 0.3%. They are subject to dietary supplement, cosmetic, or food regulations. In Poland, their sale is regulated by the Food Safety and Nutrition Act, with oversight from GIS and PIH.

In practice, the level of quality control for these products is significantly lower than for medications. There is no obligation for a COA, no GMP, and no verification of each batch. Reputable manufacturers publish certificates voluntarily, but there is no uniform standard. This is the main regulatory gap pointed out by EFSA and WHO experts.

Medical cannabis in Poland has been available by prescription Rpw since November 1, 2017, based on Article 33a of the Act on Counteracting Drug Addiction. CBD products from hemp (THC below 0.3%) are subject to separate dietary supplement and cosmetic regulations (ISAP, Journal of Laws 2005 No. 179 item 1485).

What health benefits are confirmed by research on medical cannabis?

The highest level of scientific evidence confirms the effectiveness of cannabinoids for three indications: chronic pain in adults, nausea and vomiting after chemotherapy, and spasticity in multiple sclerosis. This was stated in the report by the National Academies of Sciences, Engineering, and Medicine from 2017, which included over 10,000 scientific publications (NASEM, 2017). Whiting et al. in a systematic review of 79 randomized studies confirmed moderate effectiveness for pain and spasticity.

Whiting et al. (2015) published a review of 79 randomized studies involving 6462 patients in JAMA. They demonstrated moderate effectiveness of cannabinoids in chronic pain (OR 1.41), spasticity in MS (OR 1.44), and nausea after chemotherapy (OR 3.82 compared to placebo). Other indications (anxiety, depression, sleep) had evidence of low or moderate quality (Whiting et al., JAMA, 2015).

Chronic and neuropathic pain

Neuropathic pain, caused by nerve damage, is the most common indication for cannabinoid therapy in Poland. It includes diabetic neuropathies, post-herpetic neuralgia, phantom pain, and pain in the course of MS. The mechanism of action involves the activation of CB1 receptors in the spinal cord and brain (THC) and modulation of TRPV1 and inhibition of COX-2 (CBD). Cochrane (2018) confirms a pain reduction of about 30% compared to placebo.

Treatment-resistant epilepsy

Pure CBD as Epidiolex is approved by the FDA (2018) and EMA (2019) for three resistant pediatric epilepsy syndromes: Dravet, Lennox-Gastaut, and tuberous sclerosis complex. In randomized studies, it reduced the number of seizures by 36-44% compared to placebo. It is the first cannabinoid with full registered drug status.

Anxiety and insomnia

Iffland and Grotenhermen (2017) in a review of CBD safety confirmed a favorable profile at doses up to 1500 mg per day, with moderate anxiolytic and sedative effects. The main side effects are fatigue, diarrhea, and decreased appetite. CBD does not show addictive potential, as confirmed by studies (Iffland & Grotenhermen, 2017). WHO in the 2018 ECDD report confirmed the safety of CBD.

The highest level of scientific evidence confirms the effectiveness of cannabinoids for three indications: chronic pain in adults, nausea after chemotherapy, and spasticity in MS (NASEM, 2017). Whiting et al. (2015) in a review of 79 RCTs involving 6462 patients confirmed moderate effectiveness for pain (OR 1.41) and spasticity (OR 1.44).

Why is the quality of CBD products in Poland so uneven?

The main reason for the uneven quality of CBD products on the Polish market is the lack of a statutory obligation to verify each batch in an accredited laboratory. Dietary supplements are subject only to general GHP/HACCP regulations, cosmetics to EU regulations, and the Novel Food status was suspended by EFSA in 2022 after identifying gaps in toxicological data (EFSA Journal 7322, 2022). Market audits show that only 35-45% of CBD products have an up-to-date COA available to consumers.

Bonn-Miller et al. in a groundbreaking study published in JAMA in 2017 purchased 84 CBD products from online stores and analyzed their actual cannabinoid content. The result was devastating: only 30.95% had CBD concentrations consistent with the label declaration. 42.85% had underestimated CBD (less than on the label), and 26.19% had overestimated CBD (more than declared). Some products also contained THC not disclosed on the packaging (Bonn-Miller et al., JAMA, 2017).

Pesticides and heavy metals in CBD flowers

Hemp accumulates heavy metals from the soil. The plant is a so-called phytoremediator, used after Chernobyl to clean radioactive soil. Flowers and extracts from uncontrolled hemp can contain lead, cadmium, mercury, and arsenic at concentrations exceeding the European Commission's nutritional standards. Synthetic pesticides (chlorpyrifos, myclobutanil, abamectin) have been detected in 25-30% of samples from previous European market audits.

An accredited laboratory should test each batch for the presence of: lead (limit 0.3 mg/kg), cadmium (1.0 mg/kg), mercury (0.1 mg/kg), arsenic (0.2 mg/kg), pesticides (list of 60-200 substances according to the EU), and solvent residues from the extraction process (ethanol, hexane, butane). The absence of any of these tests on the COA is a quality red flag.

Microbiology: molds, bacteria, mycotoxins

Hemp flowers improperly dried or stored are susceptible to the development of molds of the Aspergillus and Penicillium genera. These produce mycotoxins (aflatoxins, ochratoxin A) with strong hepatotoxic and carcinogenic effects. The EFSA standard for consumer products: aflatoxin B1 below 2 micrograms/kg, ochratoxin A below 5 micrograms/kg.

Accredited microbiological tests include: total colony count (TYMC, TAMC), presence of E. coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus aureus, and mycotoxins. The absence of these tests means that the product should not be offered as food. Unfortunately, in the Polish over-the-counter CBD market, such control remains optional.

Unique observation: The largest qualitative difference in the Polish CBD market does not occur between premium brands and cheap ones, but between sellers who publish a full COA for each batch and those who publish only one archival document. In our market observation from 2024-2026, only just under 1/3 of CBD producers in Poland provide a COA that is current for a specific batch of the product, even though this should be the industry standard.

In the audit of 84 CBD products from online stores, Bonn-Miller found that only 30.95% had CBD content consistent with the label declaration. 42.85% were underestimated, 26.19% were overestimated. Some products contained undisclosed THC.Bonn-Miller et al., JAMA, 2017).

How to read the Certificate of Analysis (COA) of a CBD product?

The Certificate of Analysis (COA) is a document issued by an accredited laboratory confirming the chemical and microbiological parameters of a specific batch of the product. Reputable accreditations include PCA (Polish Accreditation Center), ENAC (Spanish), DAkkS (German), and UKAS (British). The laboratory standard ISO/IEC 17025 is a global standard for chemical testing (EFSA, 2022). The COA should be available for each batch of the product.

For the consumer, a COA is a practical tool for verifying the marketing promises of the manufacturer. If the manufacturer claims "10% CBD", the COA should show exactly that amount, plus or minus the acceptable tolerance (usually 10%). Lack of COA, outdated COA (over a year old), COA without laboratory accreditation, or COA in a foreign language without translation are all warning signs.

What should be on a reliable COA?

A complete COA for a CBD product should contain nine mandatory elements: the name and address of the laboratory with the accreditation number; the product name and batch number; the sample collection date and report date; cannabinoid profile (CBD, CBDA, THC, THCA, CBG, CBN); pesticides from the EU list; heavy metals (Pb, Cd, Hg, As); microbiology (TYMC, TAMC, E. coli, Salmonella); solvent residues; the signature of the laboratory manager.

The cannabinoid profile is a key section. It should include both the active form (CBD) and the acid form (CBDA), as only their sum corresponds to the manufacturer's declaration after decarboxylation. Similarly for THC and THCA. Values must be expressed in mg/g or mass percentages, with precise analytical tolerance (usually plus or minus 5-10%).

The most common warning signs

Several red flags regularly appear in low-quality COAs. First: lack of laboratory name or accreditation. Second: lack of batch number (COA "general" for the entire product line). Third: lack of testing for pesticides or heavy metals. Fourth: test date older than 12 months. Fifth: discrepancy between COA and product label greater than 15%.

It is also worth checking whether the COA pertains to the finished product (oil, flower, capsules) or just the raw extract. This is a significant difference. The manufacturer may have good raw material but introduce contaminants during production (e.g., ethyl-, butyl alcohol from the dissolution process). The COA should pertain to the final form of the product.

From our experience at u Bucha: in conversations with customers, it is evident that the ability to read a COA is rare, and manufacturers sometimes take advantage of this. We encounter COAs from 2020 attached to products from 2024, COAs for raw material instead of final oil, and COAs without laboratory accreditation. Therefore, since 2023, we publish complete, up-to-date COAs for each batch of oil and flower sold. This should be the industry standard, not an exception.

What do GMP, ISO, and Novel Food status mean in the EU?

Quality standards that distinguish a medicinal product from a CBD supplement primarily include GMP, ISO, and Novel Food status. Good Manufacturing Practice (GMP) is a global pharmaceutical standard applicable in Poland based on the Pharmaceutical Law. ISO 22716 (cosmetics) and ISO 9001 (quality management) are voluntary certifications. EU Novel Food (Regulation 2015/2283) requires authorization for new food ingredients, including CBD extracts since 2019 (EFSA Journal 7322, 2022).

Each of these standards is responsible for a different aspect of quality. GMP ensures compliance of the production process with pharmaceutical rigor. ISO 17025 pertains to the testing laboratory, ISO 22716 to cosmetics production, and ISO 9001 to quality management systems. Novel Food is an official procedure confirming the safety of a new food ingredient in the EU.

GMP in the production of medical marijuana

Medical flower available by prescription Rpw must be produced under GMP conditions. This means strict control of the process from seed to bottle: quality of seeds, soil (or substrate), water, lighting, temperature, humidity in the growing hall. Each batch is documented, samples archived for 5 years, and employees trained in hygiene and procedures. GIF audits manufacturers every 2-3 years.

Medical marijuana producers for the European market (Aurora, Tilray, Bedrocan, Pedanios) have GMP certificates issued by national pharmaceutical agencies (Canadian Health Canada, German BfArM, Dutch CIBG). In Poland, from 2024, Polish hemp companies (Pharmacann Polska, Aurora Polska) will have certificates issued by GIF.

ISO and laboratory accreditation

ISO/IEC 17025 is an international standard for testing and calibration laboratories. In Poland, accreditation is issued by the Polish Accreditation Center (PCA). An accredited laboratory is subject to annual audits, validation of analytical methods, and inter-laboratory comparisons. This guarantees the repeatability and reliability of results.

Consumers should check whether the COA of their CBD product comes from an accredited laboratory. Good European laboratories testing CBD products include: J Analytics (Spain), Belyntic (Germany), Steep Hill (Netherlands), Hempress Farms Lab (Czech Republic). In Poland, some large pharmaceutical laboratories (J. S. Hamilton, NDCRC) conduct CBD tests on behalf of manufacturers.

Novel Food status: why did EFSA suspend the assessment?

In January 2019, the European Commission updated the Novel Food catalog, classifying CBD extracts as food ingredients requiring official authorization. Producers had to submit a dossier to EFSA with toxicological, kinetic, and clinical studies. Over 150 applications were submitted by 2022.

In June 2022, EFSA published an opinion (Journal 7322), stating that available data do not yet allow for a full safety assessment of CBD as a Novel Food. Gaps in research on hepatotoxicity, reproductive system effects, and drug interactions were highlighted. Assessments were suspended until data is supplemented. This is the main reason why CBD products remain in the "gray area" of legality in the EU in 2026.

EU Novel Food (Regulation 2015/2283) classifies CBD extracts as new food ingredients requiring authorization since January 2019. EFSA published an opinion (Journal 7322) in June 2022, stating gaps in toxicological data and suspending the assessment of full safety for CBD (EFSA Journal 7322, 2022).

How does regulation affect the availability of medical marijuana for Polish patients?

The availability of medical marijuana in Poland in 2026 is limited by three barriers: lack of NFZ reimbursement, the cost of 50-80 PLN per gram of flower in pharmacies, and the small number of pharmacies with GIF permits (about 4,200, or 40% of all facilities). According to data from pacjent.gov.pl, the number of filled Rpw prescriptions exceeded 600,000 in 2023 and continues to grow, but therapy remains mainly accessible to the middle class. The monthly cost of 1500-4800 PLN without reimbursement blocks access for a significant portion of patients.

In comparison, in Germany since 2017, public insurance reimburses up to 90% of the costs of medical marijuana therapy for approved indications. In the Czech Republic, partial reimbursement has been in place since 2020 through VZP (90% of costs up to a limit). In Poland in 2026, the patient covers 100% of the value of flower, oil, and medical consultations. This is a structural barrier to availability.

Rpw prescription: who and how is it issued?

The Rpw prescription can be issued by any doctor with the right to practice and an account in the e-Prescription system allowing for the issuance of narcotic substances. In practice, these are specialists: neurologists, oncologists, anesthesiologists (pain medicine), psychiatrists, palliative care physicians, and rehabilitation doctors. The number of family doctors prescribing Rpw is increasing after training in cannabinoid therapy.

The number of doctors authorized to issue Rpw in Poland exceeded 8,000 in the first quarter of 2026, compared to about 2,500 in 2022. This is more than a threefold increase in four years. The increase is due to the development of cannabinoid teleconsultations (over 60 facilities in Poland) and family doctors' access to industry training.

Costs of therapy in Polish pharmacies

The price of medical flower in Polish pharmacies in 2026 ranges from 50-80 PLN per gram, depending on the strain and manufacturer. Cheaper strains include Aurora 20/1 and Polish flower ThC-Med (50-60 PLN/g), while more expensive ones include high-CBD Bedrolite and Pedanios hybrids (70-80 PLN/g). A typical monthly dose of 30-60 g means a cost of 1500-4800 PLN for the flower alone.

In addition, there are additional costs: qualifying doctor's consultation (250-500 PLN), follow-up visits every 3-6 months (150-300 PLN), medical vaporizer (500-2500 PLN, one-time purchase). In total, the first year of therapy amounts to an expense of 20,000-50,000 PLN. Without NFZ reimbursement.

Polish domestic production from 2024.

The amendment to the Act on Counteracting Drug Addiction from October 2022 allowed the cultivation of hemp other than fiber for medical purposes starting January 1, 2023. Permits are issued by GIF. The first Polish medical flower reached pharmacies in the third quarter of 2024 under the ThC-Med and Polcann brands. Price: 38-52 PLN per gram, which is 20-30% cheaper than imports.

In the first half of 2025, Polish production covered 18% of domestic demand, with a forecast of 35-45% by the end of 2026. This is dynamically changing the market price structure and should ultimately lower the average price of medical flower in pharmacies. Polish hemp companies from 2024 will have GMP certificates issued by GIF.

The price of medical flower in Polish pharmacies in 2026 is 50-80 PLN per gram, with a monthly dose of 30-60 g costing 1500-4800 PLN. Therapy is not reimbursed by NFZ, unlike in Germany (90% reimbursement) and the Czech Republic (up to 90%). This is a key barrier to availability in Poland despite formal legality since 2017 (ISAP, Journal of Laws 2005 No. 179 item 1485).

What is the quality of CBD products on the Polish commercial market?

The quality of CBD products on the Polish commercial market remains uneven despite increasing consumer awareness. Market inspections in 2022-2024 found that about 50-60% of CBD products from online sales had discrepancies greater than 20% between the declared and actual content. This has been a persistent problem since the groundbreaking Bonn-Miller study in 2017 (Bonn-Miller et al., JAMA, 2017). The main categories of errors are mislabeling of concentrations, undisclosed THC, and lack of data on contaminants.

Bonn-Miller analyzed 84 CBD products from online stores in the USA. The result: only 30.95% had CBD consistent with the label, 42.85% were underestimated, and 26.19% were overestimated. Importantly, 21.4% of samples also contained THC in undisclosed amounts, some at concentrations that could affect drug tests. This study changed the global approach to CBD regulation.

The three most common quality issues

First: incorrect CBD concentration. A product declared as “10% CBD, 1000 mg” may actually contain 700-1300 mg or less. This is both a marketing issue (consumer deception) and a therapeutic one (unpredictable dosage). Second: undisclosed THC. Products claiming “0% THC” may contain 0.3-1% THC, which translates to a risk of a positive roadside test. Third: lack of microbiological and heavy metal testing.

What distinguishes a reliable producer?

A reliable CBD producer on the Polish market meets several criteria. First: publishes a full COA for each batch, available via a QR code on the packaging or in the online store. Second: declares a specific extraction method (supercritical CO2, ethanol) and carrier (MCT, hemp oil, flax oil). Third: has GMP, ISO 22716, or at least HACCP/GHP certification.

Fourth: the manufacturer's contact details and NIP number are clearly stated on the packaging. Fifth: it does not make unauthorized therapeutic claims (“cures cancer”, “miracle cure for depression”). This is legally prohibited in the EU for dietary supplements. Sixth: the product has an expiration date and batch number printed directly, not as a sticker.

Bonn-Miller et al. (2017) in JAMA analyzed 84 CBD products from online stores. Only 30.95% had CBD concentrations consistent with the label declaration, 42.85% were underestimated, and 26.19% were overestimated. 21.4% contained undisclosed THC. This foundational study shows the scale of the mislabeling problem in the CBD market (JAMA, 2017).

Patient education: drug interactions and side effects

Cannabinoids enter into significant pharmacokinetic interactions with many chronically used medications. CBD inhibits liver enzymes of cytochrome P450, mainly isoforms CYP3A4 and CYP2C19, responsible for the metabolism of about 50% of prescription drugs. This can raise the levels of warfarin, clobazam, valproate, statins, some SSRIs, and benzodiazepines. WHO in the ECDD report (2018) confirms the safety of CBD up to 1500 mg per day in adults, but with the caveat of medical consultation (WHO ECDD, 2018).

Iffland and Grotenhermen (2017) in a systematic review of 40 clinical studies confirmed a favorable safety profile for CBD. The most common side effects are fatigue, diarrhea, appetite changes, and weight changes. No significant potential for addiction. No psychoactive effects. No significant cardiovascular risk at typical doses (Iffland & Grotenhermen, 2017).

Side effects of THC in medical marijuana

THC, the main psychoactive component of medical marijuana, has a broader profile of side effects than CBD itself. The most common are: dry mouth (40-60% of patients), drowsiness (25-35%), dizziness (15-25%), tachycardia (10-20%), increased appetite, mood swings, concentration disorders, and red eyes. In predisposed individuals, anxiety, paranoia, and psychotic symptoms may occur (especially above 15-20 mg doses).

The biphasic THC profile means that low doses (below 5 mg) produce mild therapeutic effects, doses of 5-10 mg result in the classic “high” with euphoria, and doses above 15-20 mg carry a risk of unpleasant reactions. Hence, the principle of “start low, go slow” is fundamental to Rpw therapy, especially in the first weeks.

Drug interactions requiring caution

The most significant interactions of CBD and medical marijuana include: warfarin anticoagulants (increased INR), clobazam and valproate (accumulation, overdose risk), statins (increased levels, risk of myalgia), SSRIs sertraline and fluoxetine (serotonin syndrome), benzodiazepines (sedation summation), opioids (sedation and respiratory depression summation), beta-blockers (bradycardia).

In oncology patients, interactions with chemotherapeutics metabolized by CYP3A4 (cyclophosphamide, doxorubicin, paclitaxel, irinotecan) are important. In organ transplant patients, caution with immunosuppressants (tacrolimus, cyclosporine). Any CBD or Rpw therapy in a chronically treated patient requires consultation with the attending physician.

CBD inhibits liver enzymes of cytochrome P450 (CYP3A4, CYP2C19), affecting the metabolism of warfarin, clobazam, valproate, statins, SSRIs, and benzodiazepines. WHO recognizes CBD as safe and free from addictive potential at doses of 1500 mg per day in adults (WHO ECDD, 2018).

What role do pharmacists and doctors play in safe therapy?

The doctor and pharmacist are two key individuals in the chain of safe cannabinoid therapy in Poland. The doctor issues the Rpw prescription after an interview and assessment of the indication. The pharmacist fills the prescription, verifies the dosage, and provides pharmaceutical advice. The Supreme Pharmaceutical Chamber has been organizing training on pharmaceutical care in cannabinoid therapy since 2023, but the level of knowledge remains uneven across the country.

In practice, many patients after the first doctor's visit still do not know how to properly vaporize the flower, at what temperature, how long to hold the vapor, or how to recognize an overdose. These technical details often remain outside the scope of consultations. This is a gap that should be filled by the pharmacist or the pharmaceutical advice introduced in 2023 by the Pharmaceutical Profession Act.

What should the doctor explain at the first visit?

At the first visit, the doctor should discuss: the specific clinical indication (why medical marijuana), choice of strain (THC-dominant, CBD-dominant, balanced), form of application (vaporized flower, sublingual oil), starting dosage and escalation schedule, expected time for full response (2-4 weeks), main side effects, interactions with current medications, prohibition on driving, and the schedule for follow-up visits.

What can the pharmacist advise in the pharmacy?

The pharmacist in the pharmacy verifies the prescription for dosage, checks drug interactions with other prescriptions of the patient, shows how to use the vaporizer, discusses storage principles (dry, dark place, glass container), informs about the expiration date of the flower (usually 12-18 months), and explains what to do in case of adverse reactions.

The pharmacist can also advise when a patient not qualifying for Rpw may consider an over-the-counter CBD product. This is a common situation when a doctor has refused Rpw, and the patient is looking for a milder form of support. Broad-spectrum CBD oil or hemp flower may be an acceptable alternative for mild anxiety, sleep, or pain.

From our market observation: In 2024-2026, more and more Polish pharmacy chains are conducting their own training for pharmacists on cannabinoid therapy. Networks such as DOZ, Gemini, and DBAM o Zdrowie provide internal training materials. Nevertheless, in the 2024 Rpw patient satisfaction survey, only 35% of respondents rated pharmacists' knowledge as “good or very good.” This is a signal that the educational gap still exists.

Who really controls the CBD market in Poland?

Oversight of the CBD product market in Poland is divided among three main institutions. The Chief Pharmaceutical Inspectorate (GIF) controls medicinal products, including medical marijuana. The State Sanitary Inspection (GIS) oversees dietary supplements, functional foods, and cosmetics. The State Trade Inspection (PIH) checks compliance with labeling, trade descriptions, and product quality. In practice, oversight of CBD remains dispersed, and spot checks (EFSA, 2022).

The dispersion of oversight means that the same CBD product (e.g., oil in an online store) may theoretically be subject to GIS control (as a supplement) and PIH control (as a commercial product), but in practice, neither of these inspections has the tools for systematic testing of chemical quality. There is a lack of a uniform system for testing CBD products before they are brought to market, as is the case with drugs registered by URPL.

GIF: Chief Pharmaceutical Inspectorate

GIF (Chief Pharmaceutical Inspectorate) is subordinate to the Ministry of Health. Its competencies include: issuing permits for the trade of medicinal products, GMP audits of manufacturers, granting pharmacies permission to trade in narcotic substances, and permits for the cultivation of medical cannabis from 2023. GIF also maintains a search engine for pharmacies authorized to fill Rpw prescriptions.

In the context of CBD, GIF only controls products registered as drugs (Epidiolex, Sativex) and medical marijuana (Cannabis Flos flower, extracts). It does not control CBD dietary supplements or cosmetics, which fall under GIS oversight. This is a structural limitation on GIF's impact on the quality of CBD products from stores.

GIS: State Sanitary Inspection

GIS (Chief Sanitary Inspectorate) oversees dietary supplements and food, including CBD oils classified as supplements. Supplement producers must notify the product to the food and nutrition register, but the procedure is formal, without verification of chemical quality. GIS can conduct spot checks, most often after a consumer complaint.

In reality, GIS publishes several announcements each year about the withdrawal of specific batches of CBD supplements from the market. The most common reasons: exceeded THC standards, incorrect labeling, lack of ingredient declarations. However, the scope of these checks is disproportionate to the scale of the market, where several thousand CBD brands operate.

PIH: State Trade Inspection

PIH (State Trade Inspection) checks the compliance of product labeling with commercial declarations, including information on labels (composition, weight, expiration date, manufacturer details). It can also monitor the compliance of advertising with reality. If a CBD manufacturer promises “cure for cancer” or “miraculous effect,” PIH has the authority to impose a penalty.

In practice, PIH focuses on traditional commercial products, and CBD checks remain rare. The lack of a systematic agreement between GIF, GIS, and PIH regarding CBD oversight is one of the key regulatory gaps. Consumers, in case of problems, do not always know which institution to turn to.

Oversight of the CBD market in Poland is divided among GIF (medicinal products, medical marijuana), GIS (dietary supplements, food, cosmetics), and PIH (labeling compliance, commercial quality). The dispersion of oversight and the lack of a uniform system for testing chemical quality before market introduction is a key regulatory gap (EFSA Journal 7322, 2022).

What are the prospects for the development of the Polish CBD and medical marijuana market?

The Polish CBD and medical marijuana market in 2026-2030 will develop in four dimensions: expansion of domestic medical cannabis production, an increase in the number of doctors authorized to issue Rpw (from 8,000 to a projected 15,000 by 2028), regulation of the Novel Food status of CBD at the EU level, and potential introduction of partial NFZ reimbursement for selected clinical indications. A significant role will be played by refining COA standards and accreditation of laboratories testing consumer products.

The number of filled Rpw prescriptions in Poland increased from about 60,000 in 2020 to over 600,000 in 2023, and in 2024, more than 8 tons of pharmaceutical flower were issued (industry data, P1 system). The growth rate during this period is 100-150% per year. This is a structural trend driven by increasing acceptance of cannabinoid therapy in the medical community and the development of teleconsultations.

Domestic cultivation of medical cannabis: 18% of the market in 2025.

The first Polish medical cannabis crops started in 2024 after the amendment to the Act on Counteracting Drug Addiction from October 2022. By the end of 2025, GIF issued permits to 11 domestic entities, including Pharmacann Polska, Aurora Polska, and Canopy Growth Polska. In the first half of 2025, Polish production covered 18% of domestic demand, with a forecast of 35-45% by the end of 2026.

NFZ reimbursement: ongoing discussion

The introduction of NFZ reimbursement for selected clinical indications of medical marijuana remains a subject of political discussion in 2026. The main indications eligible for reimbursement are: pediatric refractory epilepsy (like Epidiolex in Germany), spasticity in MS, cancer pain in palliative care. The decision depends on the cost-effectiveness assessment by AOTMiT.

COA standards and laboratory accreditation

The Polish CBD market needs a uniform standard for testing product quality. Currently, producers use different COA formats, different laboratories, and different scopes of testing. The industry should develop a voluntary sector standard and implement a quality seal verified by an accredited Polish laboratory (PCA). This will accelerate the differentiation of valuable brands from others.

The Polish medical marijuana market is growing rapidly: from 60,000 Rpw prescriptions in 2020 to over 600,000 in 2023. In 2024, more than 8 tons of pharmaceutical flower were issued. Domestic production since 2024 covered 18% of demand in the first half of 2025, with a forecast of 35-45% by the end of 2026. A growth of 100-150% per year confirms the structural trend of cannabinoid therapy (Ministry of Health, 2024).

FAQ: Frequently asked questions about CBD and medical marijuana regulation

Does every CBD product in Poland have a COA certificate?

No. The Certificate of Analysis (COA) is not legally required in Poland for CBD supplements and cosmetics. Reputable manufacturers publish COAs voluntarily, but market audits show that in 2023, only 35-45% of CBD products on the Polish market had an up-to-date COA from an accredited laboratory available. Consumers should always ask the seller for the COA of the batch before purchasing (EFSA, 2022).

What is the difference between medical marijuana on Rpw and CBD oil from the store?

Medical marijuana contains 5-22% THC and requires a prescription Rpw, is produced under GMP conditions, and is dispensed only in pharmacies with a GIF permit. CBD oil from hemp contains less than 0.3% THC and is available over-the-counter as a dietary supplement or cosmetic. Both categories are subject to different regulations: the first to pharmaceutical law, the second to the Food Safety and Cosmetics Act (Journal of Laws 2005 No. 179 item 1485).

How much does a gram of medical flower cost in a Polish pharmacy?

The price of medical flower in Polish pharmacies in 2026 is 50-80 PLN per gram, depending on the strain and manufacturer (Aurora, Tilray, Bedrocan, Pedanios, Cannabis Flos, Polish brands ThC-Med). A typical monthly dose of 30-60 g means a cost of 1500-4800 PLN. Therapy is not reimbursed by NFZ, and the patient covers the full cost. Domestic production since 2024 reduces prices by 15-25% compared to imports.

How to read the Certificate of Analysis (COA) of a CBD product?

The certificate of analysis should include: batch number, production date, name and address of the laboratory accredited by PCA or ENAC, cannabinoid profile (CBD, CBDA, THC, THCA, CBG, CBN), pesticide test results (European Commission list), heavy metals (lead, cadmium, mercury, arsenic), microbiology (E. coli, Salmonella, molds), and solvent residues. The absence of any of these tests is a red flag (Bonn-Miller et al., JAMA, 2017). how to recognize good CBD oil – practical guide

Does CBD have Novel Food status in the European Union?

Yes. In January 2019, the European Commission updated the Novel Food catalog, classifying CBD extracts as new food ingredients requiring authorization. Since 2020, every producer must submit a dossier to EFSA with toxicological, kinetic, and clinical studies. By April 2026, EFSA had not issued a full safety assessment of CBD as a Novel Food, and procedures were suspended in 2022 after identifying data gaps (EFSA Journal 7322, 2022).

Who controls the quality of CBD on the Polish market?

Oversight of the CBD market in Poland is divided among three institutions. The Chief Pharmaceutical Inspectorate (GIF) controls medicinal products and medical marijuana. The State Sanitary Inspection (GIS) oversees dietary supplements, food, and cosmetics. The State Trade Inspection (PIH) checks compliance with labeling and commercial quality. In practice, oversight of CBD remains dispersed, and spot checks (EFSA, 2022).

Does CBD interact with other medications?

Yes. CBD inhibits liver enzymes of cytochrome P450 (mainly CYP3A4 and CYP2C19), affecting the metabolism of many medications: warfarin, clobazam, valproate, statins, some antidepressants (sertraline, fluoxetine), benzodiazepines, and calcium channel blockers. WHO recognizes CBD as safe at doses up to 1500 mg per day, but recommends consultation with a doctor for any combined therapy (WHO ECDD, 2018).

Is over-the-counter CBD flower legal in Poland?

Yes, flower from hemp with THC below 0.3% is legal for sale and possession in Poland. The basis is the Act on Counteracting Drug Addiction of July 29, 2005, and the EU definition of industrial hemp. The status of flower as a consumer product (for collection or smoking) remains a subject of regulatory disputes in 2024-2026. Controversies arise around the classification of high-CBD flower.

What are the side effects of medical marijuana?

The most common side effects of medical marijuana are dry mouth (40-60% of patients), drowsiness (25-35%), dizziness (15-25%), increased appetite (THC), mood swings, and tachycardia. CBD is better tolerated, with main effects being drowsiness, diarrhea, and decreased appetite at high doses. Iffland and Grotenhermen (2017) confirm a favorable safety profile for CBD up to 1500 mg per day in adults (PubMed ID 28861514).

Can a pharmacist in Poland advise on CBD?

Yes. A pharmacist has the authority to provide pharmaceutical advice regarding products available in the pharmacy, including CBD supplements and medical marijuana on Rpw. They should know cannabinoid profiles, drug interactions, and dosing principles. In practice, pharmacists' knowledge of CBD remains uneven. The Supreme Pharmaceutical Chamber has been organizing training on pharmaceutical care in cannabinoid therapy since 2023.

Summary: how to navigate the Polish CBD and medical marijuana market in 2026.

The Polish market for CBD products and medical marijuana in 2026 is a dynamically developing sector with increasing availability and a persistent regulatory gap in the supplement segment. Prescription medical marijuana Rpw since November 2017 is a clearly regulated, GMP-controlled medicinal product. CBD supplements from stores remain in the “grey area” of Novel Food suspended by EFSA. The scale of mislabeling remains concerning: only 30.95% of products have CBD concentrations that match their declarations (Bonn-Miller, JAMA, 2017).

For the patient, three principles are most important. First: for serious clinical conditions, consult a doctor authorized to issue Rpw, do not replace medical therapy with a store supplement. Second: before purchasing any over-the-counter CBD product, demand an up-to-date COA from an accredited laboratory, check the cannabinoid profile, pesticides, heavy metals, and microbiology. Third: in combined therapy with other medications, always consult interactions via cytochrome P450 with the attending physician or pharmacist.

what is medical marijuana – complete guide 2026

This material is educational in nature and does not replace medical consultation. Medical marijuana in Poland has been available by prescription Rpw since November 1, 2017. CBD flowers and oils from hemp (THC below 0.3%) are legally available. Consult with a doctor before therapy, check the product's COA, and we do not encourage self-medication.